SOLICITATION NOTICE
B -- Research and Development in Biotechnology
- Notice Date
- 7/23/2010
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-(HL)-2010-232-DDC
- Archive Date
- 8/12/2010
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368, ,
- E-Mail Address
-
dc143b@nih.gov,
(dc143b@nih.gov, /div)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) intends to negotiate and award a purchase order on a noncompetitive sole source basis to Ick Young Kim, 102-201 Walkerhill Village, 383 Kwangjang-dong, Kwangjin-ku, Seoul 143-811, Korea, for the services as outlined below: The reference number NHLBI-PB-(HL)-2010-232-DDC. Background Information Chronic bacterial infections have been to shown to cause cancer via unknown mechanisms. Any bacterial product that interferes with signaling and results in the disruption of normal cell division and apoptosis could encourage tumor promotion. Similarly, the ability to promote anchorage-independent growth could facilitate metatastic potential and lead to cancer progression. One of the best-known toxic mechanisms with carcinogenic potential is the mitogenic toxin produced by some strains of Pasteurella multocida (PMT). Toxigenic P. multocida has been isolated from chronic respiratory infections in humans. PMT, a potent mitogen, enters cells, including fibroblasts, to stimulate G protein-dependent signaling pathways. In addition, mammalian targets of rapamycin (mTOR), a key Ser-Thr kinase conserved from yeast to mammals, is involved in the regulation of protein synthesis, cell growth, proliferation, and autophagy in a nutrient- and energy-responsive manner. Investigators in the Laboratory of Biochemistry (LB) have shown that PMT induces protein and ATP synthesis in serum-starved Swiss 3T3 cells via a Gαq-dependent activation of MEK and ERK1/2, and that in turn activates mTORC1, as monitored by the phosphorylation of ribosomal S6 protein and inhibited by rapamycin. Thus, MT could serve as a model for elucidating the mechanism by which a bacterial toxin is involved in tumor promotion and/or cancer progression, as well as in normal signaling pathways mediated by mTOR. Purpose and Objectives The objective is to elucidate the biochemical pathways that mediate the various responses of fibroblasts to PMT treatment. These include the mechanism underlying the anchorage-independent growth induced by transient treatment of PMT; PMT-induced mTOR activation that in turn phosphorylates PP2A, a protein phosphatase, at tyrosine 307 via a tyrosine kinase and results in its inactivation; and PMT-induced up-regulation of glucose transporter 1 protein via an mTOR-independent signaling pathway. This will lead to studies of the effects of other physiologic factors on PMT-induced responses. The Section on Metabolic Regulation in LB requires the immediate services of an expert cell biologist who has expertise in (1) enzymology, including those of protein tyrosine kinases and enzyme kinetics; (2) molecular biology, including techniques in protein overexpression and site-directed mutagenesis; and (3) protein chemistry, including techniques in protein purification and characterization. Services to be Performed General Requirments Define optimal conditions for growth, PMT-induced effect on mTOR activation, proteins and ATP synthesis, and up-regulate glucose transporter 1 (Glut 1) protein. To elucidate the molecular mechanisms by which PMT up-regulates this gene expression in serum-starved cells and to determine, using molecular biological techniques and biochemical methods, the role of Glut 1 in PMT-induced anchorage-independent proliferation. Investigate the tyrosine kinase downstream of mTOR that is responsible for phosphorylating PP2A, a protein phosphatase at tyrosine 307. Specific Requirements The contractor must have an established record as an independent investigator, and as documented by publications in peer reviewed scientific journals. The contractor must be an expert in the field of biochemistry, molecular biological techniques, and biochemical methods to study the regulation and characterization of enzymes and an expert in enzyme activity assays, including those of protein tyrosine kinase. Contractor Requirements The Contractor will perform experiments that involve growing Swiss 3T3 cells; setting up assays for enzymes participating in the signaling pathway mediating mTOR activation and PP2A inactivation that includes serine/threonine and tyrosine protein kinases, protein phosphatases, and protein synthesis machinery; carrying out siRNA methods to knockdown regulatory proteins; and site-directed mutagenesis to identify the residues involved. Reporting Requirements and Deliverables The Contractor is required to report the research findings and discuss it with the COTR on a daily basis. Program Management and Control Requirements The Contractor is expected to deliver the experimental data in a timely fashion consistent with the specific tasks defined under “Contractor Requirements”. The Contracting Officer Technical Representative (COTR) will keep abreast of the progress of the work to determine if the contract requirements are being fulfilled.. Inspection and Acceptance Requirements Inspection of the project will take place in the office of the COTR in Building 50, Room 2148, and evaluated for acceptance whether the work is acceptable. Government Requirements The government will provide on-site laboratory space; furnish all necessary laboratory chemicals, cell lines, and all instruments necessary to allow the contractor to carry out the research. Period of performance: The proposed period of performance is August 5, 2010 thru February 4, 2011. The delivery point is the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), 50 South Drive, Building 50 Room 2148, Bethesda, Maryland 20892. The sole source determination is based on the fact that the Laboratory of Biochemistry (LB) requires the services of Dr. Ick Young Kim, a former associate of the Laboratory of Biochemistry where he collaborated with Dr. Thressa C. Stadtman and also with Dr. Moon Bin Yim in Dr. Chock’s Section. In the Laboratory of Biochemistry, Dr. Kim employed molecular biological techniques and biochemical methods to study the regulation and characterization of selenophosphate synthetase. In addition, Dr. Kim is an expert in enzyme activity assays, including those of protein tyrosine kinase. He is prepared to come to Dr. Chock’s laboratory to participate in studying the mechanism by which PMT-induced mTOR activity mediates PP2A tyrosine phosphorylation as well as elucidating the molecular mechanism by which PMT regulates Glut 1 gene expression in serum-starved cells and the role of Glut 1 in PMT-induced anchorage-independent proliferation. Dr. Kim has the qualifications, experience, and expertise to carry out the proposed studies in the Laboratory of Biochemistry. His services will ensure continuity of the project in the Section on Metabolic Regulation, LB, by imparting his extensive skills to others in the laboratory who will continue with complementary lines of research. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology employee size standard are 500. The small business set-aside does not apply. This acquisition is being conducted under simplified acquisition procedures, and exempt from the requirements of FAR Part 6. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this requirement, within five (5) calendar days from publication date of this synopsis or by July 28, 2010 at 7:30am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Responses to this announcement, referencing synopsis number NHLBI-PB(HL)-2010-232-DDC may be submitted to the National Heart, Lung and Blood Institute, Consolidated Operations Acquisition Center, Procurement Branch, 6701 Rockledge Drive, Suite 6142, Bethesda, Maryland 20892-7902, Attention Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Responses will only be accepted if dated and signed by an authorized company representative. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-(HL)-2010-232-DDC/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02216566-W 20100725/100723235723-ee302bd89533989ab2743ab858e1d5d5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |